Profile data is unavailable for this security.
About the company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.
- Revenue in USD (TTM)158.30m
- Net income in USD4.74bn
- Incorporated2014
- Employees845.00
- LocationRoivant Sciences Ltd11-12 St. James's SquareSuite 1, 3rd FloorLONDON SW1Y4LBUnited KingdomGBR
- Phone+44 207 400 3347
- Websitehttp://roivant.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 219.12m | -453.82m | 5.09bn | 550.00 | -- | -- | -- | 23.25 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| ADMA Biologics Inc | 330.24m | 34.79m | 5.35bn | 624.00 | 160.87 | 28.00 | 123.92 | 16.19 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.60m | -252.45m | 5.50bn | 253.00 | -- | 4.18 | -- | 518.75 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Corcept Therapeutics Incorporated | 628.56m | 141.82m | 6.24bn | 352.00 | 46.94 | 9.74 | 43.68 | 9.93 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Elanco Animal Health Inc | 4.45bn | 205.00m | 6.96bn | 9.30k | 34.43 | 1.07 | 7.96 | 1.56 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Jazz Pharmaceuticals PLC | 3.99bn | 463.16m | 7.63bn | 2.80k | 17.41 | 1.79 | 6.84 | 1.91 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 7.76bn | 373.00 | 20.18 | 17.13 | 16.37 | 8.19 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Roivant Sciences Ltd | 158.30m | 4.74bn | 8.78bn | 845.00 | 2.13 | 1.61 | 1.89 | 55.45 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 613.73m | -86.37m | 9.68bn | 610.00 | -- | 8.45 | -- | 15.77 | -0.8595 | -0.8595 | 6.10 | 10.80 | 0.6011 | 1.42 | 4.94 | 1,006,112.00 | -8.46 | -38.27 | -9.74 | -42.77 | 92.30 | -- | -14.07 | -128.42 | 7.51 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Catalent Inc | 4.42bn | -413.00m | 10.78bn | 16.90k | -- | 3.04 | 140.05 | 2.44 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Biomarin Pharmaceutical Inc | 2.75bn | 322.29m | 12.78bn | 3.40k | 40.34 | 2.36 | 30.29 | 4.64 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 01 Jul 2024 | 69.37m | 9.38% |
| QVT Financial LPas of 26 Sep 2024 | 63.93m | 8.64% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 46.55m | 6.30% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 41.68m | 5.64% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 31.15m | 4.21% |
| Morgan Stanley Investment Management, Inc.as of 30 Jun 2024 | 26.64m | 3.60% |
| Rubric Capital Management LPas of 30 Jun 2024 | 23.00m | 3.11% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 18.44m | 2.49% |
| Two Seas Capital LPas of 30 Jun 2024 | 10.32m | 1.40% |
| Woodline Partners LPas of 30 Jun 2024 | 8.00m | 1.08% |
